Ganglioside GM1
- Generic Name
- Ganglioside GM1
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C73H131N3O31
- CAS Number
- 116950-37-9
- Unique Ingredient Identifier
- 562413257Z
- Associated Conditions
- -
- Associated Therapies
- -
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 98
- Registration Number
- NCT05751668
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Morton Plant Hospital, Clearwater, Florida, United States
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 51
- Registration Number
- NCT04395339
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02093910
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China,, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath